Personalized Medicine Convention

The International Event for Personalized Medicine

Cologne // 30.11. + 01.12.2016

Save the Date!  7. PerMediCon, April 18th + 19th 2018, Theater am Tanzbrunnen, Cologne

PerMediCon

Congress

Exhibition

Call-for-Projects

Tickets

Travel

Contact

de // en

Call for Projects

For the third time PerMediCon awards three innovative and application-oriented projects - whether research or industry referred - aimed at products, technologies and services in the context of personalized medicine with an award and three cash prizes.

 

What?

Projects related to personalized medicine in the fields of biotechnology, diagnostics, healthcare IT, medical technology and pharmaceuticals.

 

Who?

Research institutions and companies (startups, SMBs, large companies).

 

Jury:

Delegated members of the program committee of PerMediCon.

 

Criteria:

Related to personalized medicine, innovation character, user benefits.

 

Your benefits:

All 15 formally submitted projects which met the above criteria, participate at the PerMediCon 2016 with a poster of the project. They receive two PerMediCon season tickets, a certificate of participation and get one ticket to participate at the Networking-Night PerMediCon 2016.

 

In addition, the selected projects are introduced with a 3-minute PowerPoint presentation in the exhibition on the first day of the congress.

 

The three projects with the highest jury rating get a further 5-minute PowerPoint presentation in the conference program on the second day. There are cash prizes over 1,500 Euro, 1,000 Euro and 500 Euro. Theᅠ best ranked project receives the PerMediCon Award 2016.

 

Winners 2015

These are the 2015 PerMediCon contest winners:

 

1. Price:

Hasso-Plattner-Institut für Softwaresystemtechnik GmbH, University of Potsdam, Project "Drug Response Analysis“, represented by Dr. Konrad Klinghammer

 

2. Price:

Institut für Pathologie, Uniklinik der RWTH Aachen, Project "QITHERA: Novel anti-cancer compounds to treat triple negative breast cancer (TNBC)”, represented by Dr. Michael Rose

 

3. Price:

NEO New Oncology AG, Cologne, Project “NEOliquid – A blood based, non-invasive test to identify all genomic alterations relevant to therapy of cancer patient”, represented by Dr. Christian Glöckner